title: Chemoprotection and enhancement of cancer chemotherapeutic efficacy of cyclophosphamide in mice bearing Ehrlich ascites carcinoma by diphenylmethyl selenocyanate.
abstract: OBJECTIVE
  Chemoprotective effect of diphenylmethyl selenocyanate against cyclophosphamide (CP) induced cellular toxicity and antitumor efficacy was evaluated in mice bearing Ehrlich ascites carcinoma.
  
  
  METHODS
  Diphenylmethyl selenocyanate (3 mg/kg.b.w.) was administered orally and CP was given intraperitoneally (25 mg/kg.b.w). The effects were observed on the level of lipid peroxidation, antioxidant enzymes status, serum transaminase (ALT, AST) activity, hematological profile, transplantable murine tumor growth, apoptosis induction in tumor cells, and life span of tumor bearing hosts.
  
  
  RESULTS
  The selenium compound restored the levels of antioxidant enzymes system, decreased the level of lipid peroxidation and serum transaminase activity. Hematological profile reverted to near normal level after selenium compound treatment. Treatment with the selenium compound also resulted in significant tumor growth regression along with significant upregulation of apoptosis, increased in mean survival time and life span of tumor bearing host.
  
  
  CONCLUSIONS
  Results clearly indicate that diphenylmethyl selenocyanate has the potential to reduce the cellular toxicity of CP at the same time improving its antitumor efficacy.
authors.affiliation: Department of Cancer Chemoprevention, Chittaranjan National Cancer Institute, Kolkata, West Bengal, India.
authors.forename: Pramita
authors.initials: P
authors.lastname: Chakraborty
authors.forename: Ugir Hossain
authors.initials: UH
authors.lastname: Sk
authors.forename: Sudin
authors.initials: S
authors.lastname: Bhattacharya
mesh_terms: D000410:Alanine Transaminase / Q000378:metabolism; D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D000975:Antioxidants / Q000378:metabolism; D017209:Apoptosis / Q000187:drug effects; D001219:Aspartate Aminotransferases / Q000378:metabolism; D001772:Blood Cell Count; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy* / Q000473:pathology; D002374:Catalase / Q000378:metabolism; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004357:Drug Synergism; D005978:Glutathione / Q000378:metabolism; D005979:Glutathione Peroxidase / Q000378:metabolism; D005982:Glutathione Transferase / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D051379:Mice; D016566:Organoselenium Compounds / Q000494:pharmacology*; D013482:Superoxide Dismutase / Q000378:metabolism; D016019:Survival Analysis
chemical_list: D018906:Antineoplastic Agents, Alkylating; D000975:Antioxidants; D016566:Organoselenium Compounds; C495419:diphenylmethyl selenocyanate; D003520:Cyclophosphamide; D002374:Catalase; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D005982:Glutathione Transferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D005978:Glutathione